文献速递消化道肿瘤与早癌消化内镜

系统综述与荟萃分析:阿司匹林与筛查预防结直肠癌效果的比较

Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-17

该系统综述与网络荟萃分析检索至2015年10月31日的随机试验,比较阿司匹林与愈创木脂粪隐血试验(FOBT)或软式乙状结肠镜筛查对结直肠癌发病和死亡的影响,发现低剂量阿司匹林在降低总体发病和死亡方面似乎与筛查等效,对近端结肠癌更有效。

要点

  • 阿司匹林降低结直肠癌死亡率的效果与FOBT(RR 1.03;95% PrI 0.76-1.39)和软式乙状结肠镜(RR 1.16;95% PrI 0.84-1.60)相似。
  • 阿司匹林在预防近端结肠癌死亡或发病方面优于FOBT(RR 0.36;95% PrI 0.22-0.59)和软式乙状结肠镜(RR 0.37;95% PrI 0.22-0.62)。
  • 降低结直肠癌发病率方面阿司匹林与筛查等效,软式乙状结肠镜优于FOBT(RR 0.84;95% PrI 0.72-0.97)。

核心结论

  • 低剂量阿司匹林在降低结直肠癌发病率和死亡率方面似乎与软式乙状结肠镜或愈创木脂FOBT筛查等效,且对近端结肠癌更有效。
  • 需要开展阿司匹林与筛查比较的随机有效性试验。

研究设计与样本

  • 系统综述与网络荟萃分析,检索Medline、EMBASE和Cochrane中心注册库(CENTRAL)截至2015年10月31日的随机试验。
  • 纳入平均风险人群中报告结直肠癌死亡率、发病率或两者、随访至少2年、随机化个体超过100例的随机试验。
  • 由三名研究者独立提取数据,采用频率学派网络荟萃分析计算相对危险度(RR)及95%预测区间(PrI)。

主要发现

  • 阿司匹林对结直肠癌死亡率的影响与FOBT相似(RR 1.03;95% PrI 0.76-1.39),与软式乙状结肠镜也相似(RR 1.16;95% PrI 0.84-1.60)。
  • 阿司匹林在预防近端结肠癌死亡或发病方面优于FOBT(RR 0.36;95% PrI 0.22-0.59),也优于软式乙状结肠镜(RR 0.37;95% PrI 0.22-0.62)。
  • 降低结直肠癌发病率方面阿司匹林与筛查等效,软式乙状结肠镜优于FOBT(RR 0.84;95% PrI 0.72-0.97)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both aspirin use and screening with flexible sigmoidoscopy or guaiac faecal occult blood testing (FOBT) may reduce mortality from colorectal cancer, but comparative effectiveness of these interventions is unknown. AIM: To compare aspirin to guaiac FOBT screening with regard to incidence and mortality of colorectal cancer in a network meta-analysis. METHODS: We searched Medline, EMBASE and the COCHRANE central register (CENTRAL) for relevant randomised trials identified until 31 October 2015. Randomised trials in average-risk populations that reported colorectal cancer mortality, colorectal cancer incidence, or both, with a minimum follow-up of 2 years, and more than 100 randomised individuals were included. Three investigators independently extracted data. We calculated relative risks [RR with 95% predictive intervals (PrIs)] for the comparison of the interventions by frequentist network meta-analyses. RESULTS: The effect of aspirin on colorectal cancer mortality was similar to FOBT (RR 1.03; 95% PrI 0.76-1.39) and flexible sigmoidoscopy (RR 1.16; 95% PrI 0.84-1.60). Aspirin was more effective than FOBT (RR 0.36; 95% PrI 0.22-0.59) and flexible sigmoidoscopy (RR 0.37; 95% PrI 0.22-0.62) in preventing death from or cancer in the proximal colon. Aspirin was equally effective as screening in reducing colorectal cancer incidence, while flexible sigmoidoscopy was superior to FOBT (RR 0.84; 95% PrI 0.72-0.97). CONCLUSIONS: Low-dose aspirin seems to be equally effective as flexible sigmoidoscopy or guaiac FOBT screening to reduce colorectal cancer incidence and mortality, and more effective for cancers in the proximal colon. A randomised comparative effectiveness trial of aspirin vs. screening is warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Emilsson L, Holme Ø, Bretthauer M, et al. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther. 2016. PMID: 27859394. doi:10.1111/apt.13857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。